Medical technologies assessment in COVID-19

Author:

Kolbin A. S.1ORCID,Gomon Yu. M.2

Affiliation:

1. Pavlov First St. Petersburg State Medical University; St. Petersburg State University

2. Pavlov First St. Petersburg State Medical University

Abstract

According to official information about the coronavirus, as of May 2023, about 400 thousand people died from COVID-19 in Russia, 6.9 million people in the world. Social, as well as medical and economic aspects are associated with the COVID-19 pandemic. The main global financial resources were allocated to the provision of vaccines ($13.8 billion, 40.4%); reorganization of health systems ($4.1 billion); COVID-19 drug therapy ($3.4 billion). The costs of research, development and study of vaccines and medicines accounted for only 0.6% of total costs ($166 million). The article presents a clinical and pharmacological analysis of various medicines recommended for the treatment of infection. In these conditions, the reliability and effectiveness of national health technology assessment systems has become particularly relevant.

Publisher

Baltic Medical Education Center

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Immunology

Reference44 articles.

1. The international network of agencies for health technology assessment (INAHTA). https://www.inahta.org/

2. Kurylev A.A., Zhuravkov A.A., Kolbin A.S. Real clinical practice in the assessment of healthcare technologies: the state for 2022. Real clinical practice: data and evidence. 2022, Vol. 4, No. 3, рр. 1–9 (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-21.

3. Federal Law «On Circulation of Medicines» dated 12.04.2010 No. 61-FZ (ed. dated 26.03.2022). Article 4. The basic concepts used in this Federal Law and Article 60. State regulation of prices for medicines for medical use (In Russ.)

4. Nordon C., Karcher H., Groenwold R.H. et al.; GetReal consortium. The «Efficacy-Effectiveness Gap»: Historical Background and Current Conceptualization // Value Health. 2016. Vol. 19, No. 1. Р. 75–81. doi: 10.1016/j.jval.2015.09.2938.

5. Kolbin A.S. et al. Research of real clinical practice. Moscow: OKI Publishing House: Buki Vedi, 2020. 208 p.: ill. (In Russ.) ISBN 978-5-4465-2902-5.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3